{"result": {"id": "3a7ae5e2-6980-43b1-bd00-ca8260b19afa", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>ALDEHYDE DEHYDROGENASE<|>organization<|>An enzyme that plays a key role in alcohol metabolism, inhibited by disulfiram in disulfiram-like reactions>)\n##\n(\"entity\"<|>ETHANOL<|>organization<|>An alcohol whose metabolism is disrupted in disulfiram-like reactions when aldehyde dehydrogenase is inhibited>)\n##\n(\"entity\"<|>ACETALDEHYDE<|>organization<|>A toxic metabolite of ethanol that accumulates during disulfiram-like reactions>)\n##\n(\"entity\"<|>5-HYDROXYTRYPTAMINE<|>organization<|>A neurotransmitter whose excessive activity causes 5-hydroxytryptamine syndrome>)\n##\n(\"entity\"<|>MACROLIDES<|>organization<|>A class of antibiotics that can cause mechanism-based inhibition of CYP3A4>)\n##\n(\"entity\"<|>CIMETIDINE<|>organization<|>A drug that causes non-selective inhibition of multiple CYP450 isoenzymes including CYP3A4, CYP2D6 and CYP1A2>)\n##\n(\"entity\"<|>DPP-4 INHIBITORS<|>organization<|>A class of drugs including linagliptin that inhibit dipeptidyl peptidase-4>)\n##\n(\"entity\"<|>ACE INHIBITORS<|>organization<|>A class of drugs whose angioedema risk may be increased by DPP-4 inhibitors>)\n##\n(\"relationship\"<|>DISULFIRAM-LIKE REACTION<|>ALDEHYDE DEHYDROGENASE<|>Disulfiram-like reactions occur when disulfiram inhibits aldehyde dehydrogenase<|>9)\n##\n(\"relationship\"<|>DISULFIRAM-LIKE REACTION<|>ETHANOL<|>Disulfiram-like reactions involve abnormal metabolism of ethanol<|>8)\n##\n(\"relationship\"<|>DISULFIRAM-LIKE REACTION<|>ACETALDEHYDE<|>Disulfiram-like reactions cause accumulation of toxic acetaldehyde<|>8)\n##\n(\"relationship\"<|>5-HYDROXYTRYPTAMINE SYNDROME<|>5-HYDROXYTRYPTAMINE<|>The syndrome results from excessive 5-hydroxytryptamine activity<|>9)\n##\n(\"relationship\"<|>MECHANISM-BASED INHIBITION<|>MACROLIDES<|>Macrolides can cause mechanism-based inhibition of CYP3A4<|>8)\n##\n(\"relationship\"<|>NON-SELECTIVE INHIBITION<|>CIMETIDINE<|>Cimetidine causes non-selective inhibition of multiple CYP450 enzymes<|>8)\n##\n(\"relationship\"<|>LINAGLIPTIN<|>DPP-4 INHIBITORS<|>Linagliptin belongs to the class of DPP-4 inhibitors<|>9)\n##\n(\"relationship\"<|>DPP-4 INHIBITORS<|>ACE INHIBITORS<|>DPP-4 inhibitors may increase risk of ACE inhibitor-associated angioedema<|>7)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752166633, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 709, "prompt_tokens": 3688, "total_tokens": 4397, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 3648}, "prompt_cache_hit_tokens": 3648, "prompt_cache_miss_tokens": 40}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 白超家族，在肝脏中的含量最丰富，与肝脏疾病关系 密切。CYP450 是一个单氧化酶家族，对人类的 Ⅰ相 药物代谢具有重要意义，能催化大量内源性和外源性 复合物的代谢，包括异生物质、药物、环境毒物、类 固醇和脂肪酸等。\n　　　· 双硫仑样反应（disulfiram-like reaction）：又 称双硫醒样反应或酒醉貌反应，指双硫仑抑制乙醛脱 氢酶，阻挠乙醇的正常代谢，致使饮用少量乙醇也可 引起乙醛中毒的反应。对于一般较轻的反应，不需治 疗可自行恢复。若出现剧烈反应，如呼吸抑制、虚脱、 惊厥、心功能失常时应采取相应措施救治。\n　　　·5- 羟色胺综合征（5-HTS）：神经系统中 5- 羟色胺功能亢进所引起的一组症状和体征，主要临床 表现是认知功能和行为改变、神经肌肉异常、 自主神 经功能不稳定等。是由药物及其相互作用产生的中枢 和外周神经系统细胞突触间隙5- 羟色胺递质浓度过 多所致的药物不良反应，有可能危及生命，多数由治 疗性药物、故意限药或意外药物相互作用引起。\n　　　· 酶的底物（substrates）：在生物化学领域指参 与生化反应的物质，可为化学元素、分子或化合物， 经酶作用可形成产物。一个生化反应的底物常同时也 是另一个化学反应的产物。\n　　　· 抑制剂（inhibitors）：药酶活性减弱，使其他 药物或本身代谢减慢，占代谢性相互作用的 70%。\n　　　·诱导剂（inducers）：药酶活性增强，使其他 药物或本身代谢加速，占代谢性相互作用的 23%。\n　　　·竞争性抑制：通常当两种药物均是同一个酶的 底物时，底物之间产生竞争，抑制彼此的代谢。\n　　　·机制基础抑制：也叫自杀性抑制，如大环内酯 类经 CYP3A4 代谢，代谢物可与 CYP450 分子中血红 蛋白的亚铁形成亚硝基烷烃复合物而使酶失活。\n　　　· 非选择性抑制：指药物对多个 CYP450 同工酶 均有抑制作用，缺乏选择性。如西咪替丁可同时抑制 CYP3A4 、CYP2D6 、CYP1A2。\n\n\npharmacokinetics and pharmacodynamics of linagliptin［J］ .\nCl in  Pharm ac oki net ，2 0 1 2 ，5 1（ 7 ）：4 1 1 -4 2 7 . DOI： 10.2165/11630900-000000000-00000.\n［ 20］BROWN  N  J ， BYIE RS  S ， CAR R  D ， et  al. Dip ep tidy l peptidase-  Ⅳ inhibitor use associated with increased risk of ACE inhibitor-associated angioedema［J］.Hypertension，2009，54（ 3 ）： 516-523.DOI：10.1161/HYPERTENSIONAHA.109.134197.\n（收稿日期：2018-08-23 ） （本文编辑：陈素芳）\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>CYP450<|>organization<|>CYP450 is a family of monooxygenases important in human phase I drug metabolism, catalyzing the metabolism of various endogenous and exogenous compounds including xenobiotics, drugs, environmental toxins, steroids, and fatty acids>)\n##\n(\"entity\"<|>DISULFIRAM-LIKE REACTION<|>event<|>A disulfiram-like reaction occurs when disulfiram inhibits aldehyde dehydrogenase, disrupting normal ethanol metabolism and causing acetaldehyde toxicity even with small amounts of alcohol consumption>)\n##\n(\"entity\"<|>5-HYDROXYTRYPTAMINE SYNDROME<|>event<|>5-Hydroxytryptamine syndrome is a condition caused by excessive serotonin activity in the nervous system, leading to cognitive, behavioral, neuromuscular, and autonomic nervous system abnormalities, often due to drug interactions>)\n##\n(\"entity\"<|>SUBSTRATES<|>organization<|>Substrates are substances that participate in biochemical reactions, which can be chemical elements, molecules, or compounds, and are transformed into products by enzymatic action>)\n##\n(\"entity\"<|>INHIBITORS<|>organization<|>Inhibitors reduce enzyme activity, slowing the metabolism of other drugs or themselves, accounting for 70% of metabolic interactions>)\n##\n(\"entity\"<|>INDUCERS<|>organization<|>Inducers enhance enzyme activity, accelerating the metabolism of other drugs or themselves, accounting for 23% of metabolic interactions>)\n##\n(\"entity\"<|>COMPETITIVE INHIBITION<|>event<|>Competitive inhibition occurs when two drugs are substrates of the same enzyme, competing and inhibiting each other's metabolism>)\n##\n(\"entity\"<|>MECHANISM-BASED INHIBITION<|>event<|>Mechanism-based inhibition, or suicidal inhibition, involves metabolites forming irreversible complexes with enzymes, such as macrolides with CYP3A4, leading to enzyme inactivation>)\n##\n(\"entity\"<|>NON-SELECTIVE INHIBITION<|>event<|>Non-selective inhibition refers to drugs inhibiting multiple CYP450 isoenzymes without specificity, such as cimetidine inhibiting CYP3A4, CYP2D6, and CYP1A2>)\n##\n(\"entity\"<|>LINAGLIPTIN<|>organization<|>Linagliptin is a drug studied for its pharmacokinetics and pharmacodynamics, as referenced in clinical pharmacology literature>)\n##\n(\"entity\"<|>BROWN N J<|>person<|>Brown NJ is a researcher associated with studies on DPP-4 inhibitors and their risks, such as ACE inhibitor-associated angioedema>)\n##\n(\"entity\"<|>BYIE RS S<|>person<|>Byiers S is a co-author in research on DPP-4 inhibitors and their interactions>)\n##\n(\"entity\"<|>CAR R D<|>person<|>Carr D is a co-author in research on DPP-4 inhibitors and their interactions>)\n##\n(\"relationship\"<|>DISULFIRAM-LIKE REACTION<|>CYP450<|>Disulfiram-like reactions involve CYP450 enzymes in the metabolism of ethanol and acetaldehyde<|>6)\n##\n(\"relationship\"<|>5-HYDROXYTRYPTAMINE SYNDROME<|>CYP450<|>5-Hydroxytryptamine syndrome can result from drug interactions involving CYP450 enzymes<|>5)\n##\n(\"relationship\"<|>SUBSTRATES<|>CYP450<|>Substrates are metabolized by CYP450 enzymes in biochemical reactions<|>7)\n##\n(\"relationship\"<|>INHIBITORS<|>CYP450<|>Inhibitors reduce the activity of CYP450 enzymes, affecting drug metabolism<|>8)\n##\n(\"relationship\"<|>INDUCERS<|>CYP450<|>Inducers increase the activity of CYP450 enzymes, accelerating drug metabolism<|>8)\n##\n(\"relationship\"<|>COMPETITIVE INHIBITION<|>CYP450<|>Competitive inhibition involves CYP450 enzymes when multiple substrates compete for the same enzyme<|>7)\n##\n(\"relationship\"<|>MECHANISM-BASED INHIBITION<|>CYP450<|>Mechanism-based inhibition involves irreversible inactivation of CYP450 enzymes by certain metabolites<|>8)\n##\n(\"relationship\"<|>NON-SELECTIVE INHIBITION<|>CYP450<|>Non-selective inhibition affects multiple CYP450 isoenzymes simultaneously<|>7)\n##\n(\"relationship\"<|>BROWN N J<|>LINAGLIPTIN<|>Brown NJ has researched drugs like linagliptin and their pharmacokinetic interactions<|>4)\n##\n(\"relationship\"<|>BYIE RS S<|>LINAGLIPTIN<|>Byiers S has co-authored research on drugs like linagliptin<|>3)\n##\n(\"relationship\"<|>CAR R D<|>LINAGLIPTIN<|>Carr D has co-authored research on drugs like linagliptin<|>3)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_c8f079dba7b5021458eae98df2e3de858a68c1c0a3b17aef6b0d75c27a749529_v2"}